Skip to main content

Statins at the end of life, revisited

The recently published statin-discontinuation trial  has been celebrated in the palliative care community.  It’s message is clear – go ahead and stop statins in patients nearing the end of life. 

Or is it?

I’ll offer a contrarian viewpoint: the trial does not reliably prove that people are helped by stopping statins in the final year or so of life. 

Why this “downer” message?  It’s because the study had insufficient power to assess if there are clinically meaningful differences between people who were randomized to stop their statin and those who were randomized to continue.  This is no fault of the investigators; the study was carefully planned and thoughtfully designed.   However, participants lived three times longer than expected (an average of 9 months, compared with a projected average of 3 months).  As a result, the original sample size projections and outcome analysis were jettisoned.  In consultation with the trial’s data safety and monitoring board, a new outcome of 60-day mortality was substituted. 

The results showed that 23.8% of people who stopped statins died within 60 days, compared with 20.3% who continued statins - a difference of 3.5%.   In other words, if you took 100 people nearing the end of life and stopped their statin, 3 ½ more of them would die because you stopped the statin than if you had continued statin therapy.  But, because the sample size of the study was relatively small (381), there is a lot of uncertainty in that estimate.  The true effect of discontinuing statins could be anywhere from causing 3 ½ fewer deaths to causing 10 ½ more deaths.   (This is based on the stated 90% confidence intervals of -3.5% to 10.5%) 

What does this mean in plain English?  Stopping statins may cause more people to die.  It may cause fewer people to die.  It may make no difference.  We just don’t know.   In contrast, it is incorrect to say that this trial proves that stopping statins has no effect on mortality.

Fortunately (or not), death is not the only outcome that’s important to people with advanced terminal disease.  The trial revealed some interesting findings around quality of life.  People who stopped statins had better “total” quality of life on a score-based measure.  However, the main factors that contributed to these better scores were perceptions of having better support and well-being, whereas physical and other elements of quality of life were no different.  Similarly, physical symptoms and performance status were similar between people who continued vs. stopped statins.   It’s hard to know what to make of these results; they are intriguing, but hardly an unequivocal endorsement for stopping statins.

This is not to say that statins are harmless.  Their side effects are well-documented, although the frequency of perhaps their most important side effect – a feeling of muscle aches and malaise – has been very difficult to pin down.  (These symptoms occur reasonably often, but in many if not most cases they are not due to statins).  There has also been concern that statins might worsen cognitive function by interfering with lipid metabolism in the brain.  Recent reviews  on this topic are reassuring, although statins in late life probably do not confer cognitive benefits either

Does the lack of a clear positive result from the statin discontinuation trial mean that we should continue statins for all people with advanced terminal illness?  Of course not.  This decision should be guided by the patient’s goals of care, their actual experience with and potential side effects from statins, and so forth.  Most studies do not provide an unequivocal answer to clinical questions, and this study is no different.  Yet, it does provide useful information that deepens our understanding of the potential benefits and harms of statins in this setting.  For that we should thank the investigators and all of the people who participated in the trial.

by: Mike Steinman

Comments

Jim Richardson said…
Thank you for expressing my thoughts exactly. Palliative care should be the exact opposite of the "one size fits all mentality." As a geriatrician as well as a palliative medicine practitioner, I'm all for stopping harmful or useless drugs, but these should be thoughtful, individualized decisions.
Ravi Ramaswamy said…
Excellent review and commentary on this recent interesting article, Mike. Thanks very much. One thing I will add is about the lack of evidence for the benefit of statins in older patients (>75 years), in whom we already base our clinical decisions on our beliefs and patient preferences. For "older patients" with advanced and life-limiting illness, this study may help with bolstering our discussions about discontinuing statins.
It's interesting that some of our "quality measures" evaluates our care based on statin use and LDL levels in these old-old patients with and without advanced illness.
kopiluwak nya said…
This comment has been removed by a blog administrator.

Popular posts from this blog

Caring, and the Family Caregivers We Don’t See

Over lunch at a restaurant in Manhattan, my father and I talked about long-term care insurance and the emergence of senior centers and nursing homes across the U.S. that offer a variety of ethnic cuisines and cultural events, catering not only to a growing population of adults over 65, but also, to an increasingly diverse population of adults who call the U.S. their home. This conversation was different from many similar ones before it – we weren’t talking about my research; we were talking about our own lives.
My parents immigrated to the U.S. in the late ‘70s and early ‘80s, following their parents’ advice on professional opportunities that seemed unimaginable in India at the time. Although they considered moving back soon after to care for their aging parents and to raise children, they ultimately decided to stay in the U.S. As I chronicled earlier, my paternal grandparents lived with us until I completed middle school, at which point they returned to India and lived with my mater…

Practical Advice for the End of Life: A Podcast with BJ Miller

This week we talk with BJ Miller, hospice and palliative care physician, public speaker, and now author with Shoshana Berger of the book "A Beginner's Guide to the End."

As we note on the podcast, BJ is about as close as we get to a celebrity in Hospice and Palliative Care.  His TED Talk "What Really Matters at the End of Life" has been viewed more than 9 million times.  As we discuss on the Podcast, this has changed BJ's life, and he spends most of his working time engaged in public speaking, being the public "face" of the hospice and palliative care movement.

The book he and Berger wrote is filled to the brim with practical advice.  I mean, nuts and bolts practical advice.  Things like:
How to clean out not only your emotional house but your physical house (turns out there are services for that!)Posting about your illness on social media (should you post to Facebook)What is the difference between a funeral home and mortuaryCan I afford to die?  …

Top 25 Studies in Hospice and Palliative Care (#HPMtop25)

by: Kara Bishoff (@kara_bischoff )

Back in 2015 we wrote a post asking for input on what articles should belong on a list of the top 25 articles in hospice and palliative care.   We decided to focus on hospice palliative care studies and trials - as opposed to review articles, consensus statements and opinion pieces.

Here’s what we came up with. It was hard to pick just 25! We highly prioritized clinical utility and tried to achieve diversity & balance. Many others are worthy of inclusion. Take a look and let us know if you have suggested changes for next year.

Module 1: Symptom Management
Randomized, Double-Blind, Placebo-Controlled Trial of Oral Docusate in the Management of Constipation in Hospice Patients. Tarumi Y et al. JPSM, 2013.Once-Daily Opioids for Chronic Dyspnea: A Dose Increment and Pharmacovigilance Study. Currow DC et al. JPSM, 2011.Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomise…